polsar 60 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - ticagrelorum - apvalkotā tablete - 60 mg
polsar 90 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - ticagrelorum - apvalkotā tablete - 90 mg
tilobrastil 60 mg apvalkotās tabletes
sandoz pharmaceuticals d.d., slovenia - ticagrelorum - apvalkotā tablete - 60 mg
tilobrastil 90 mg apvalkotās tabletes
sandoz pharmaceuticals d.d., slovenia - ticagrelorum - apvalkotā tablete - 90 mg
ticagrelor viatris 90 mg apvalkotās tabletes
viatris limited, ireland - ticagrelorum - apvalkotā tablete - 90 mg
ticagrelor zentiva 90 mg apvalkotās tabletes
zentiva, k.s., czech republic - ticagrelorum - apvalkotā tablete - 90 mg
plategra 60 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - ticagrelorum - apvalkotā tablete - 60 mg
plategra 90 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - ticagrelorum - apvalkotā tablete - 90 mg
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
ticagrelor elvim 90 mg apvalkotās tabletes
elvim, sia, latvia - ticagrelorum - apvalkotā tablete - 90 mg